scFv(CD20)-CD3zeta CAR-T Lentivirus

The scFv(CD20)-CD3zeta CAR-T lentivirus is a research-grade lentiviral particle preparation designed to deliver a first-generation anti-CD20 chimeric antigen receptor (CAR), which is composed of a CD20-specific single-chain variable fragment (scFv) fused to a CD3ζ signaling domain. This vector is constructed on a modern, safety-engineered lentiviral backbone, supporting durable genomic integration and long-term expression in human T cells, enabling sustained CAR expression on the cell surface for long-term functional assessment. The platform emphasizes high functional consistency, reliable gene delivery to primary cells, and reduced risk of promoter silencing, supporting reproducible experiments at multiple time points.

This lentiviral product is suitable for a wide range of applications in the field of CD20-targeted immunotherapy, including drug discovery, preclinical research, and translational method development. It supports in vitro modeling of CD20-expressing B-cell malignancies, including studies of diseases such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. Researchers can utilize this system to assess the impact of antigen density dependence, epitope accessibility, and microenvironmental factors on CAR function, enabling hypothesis-driven comparisons across different cell states, tumor models, and co-stimulatory pathways. Furthermore, it can be integrated into target validation, off-target risk assessment in normal B cell subsets, and exploratory safety pharmacology platforms, providing a basis for rational design choices for subsequent constructs. In vivo, this tool can be used for fundamental modeling of antitumor activity and persistence in appropriate animal models, helping to assess exposure-response relationships and resistance mechanisms.